SCHEMBL4066934

SCHEMBL4066934

NS(=O)(=O)c1ccc(CCNc2ncnc3cc(-c4ccccc4)sc23)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 4/20 0.54
CA2 P00918 4/20 0.54
CA7 P43166 3/20 0.54
CA13 Q8N1Q1 3/20 0.54
HTT P42858 3/20 0.53
LMNA P02545 2/20 0.53
ALDH1A1 P00352 2/20 0.53
GALR3 O60755 1/20 0.53
NR2F2 P24468 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
KCNH2 Q12809 2/20 0.52
FLT1 P17948 5/20 0.50
HPGD P15428 1/20 0.50
MAPT P10636 2/20 0.48
TP53 P04637 1/20 0.48
IKBKB O14920 1/20 0.47
KDM4E B2RXH2 1/20 0.47
MEN1 O00255 1/20 0.47
GAA P10253 1/20 0.47
KMT2A Q03164 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4067658 0.87 FLT1 (0.61) HTTLMNAALDH1A1FLT1IKBKB
SCHEMBL4072529 0.84 TYK2 (0.60) HTTLMNAFLT1IKBKBKIT
SCHEMBL4071814 0.84 FLT1 (0.55) HTTLMNAALDH1A1NR2F2FLT1
SCHEMBL4069349 0.81 FLT1 (0.57) HTTLMNAALDH1A1KCNH2FLT1
SCHEMBL13242725 0.79 AURKA (0.59) FLT1EGFR
SCHEMBL4069671 0.78 NPR1 (0.54) HTTLMNAALDH1A1FLT1HPGD
SCHEMBL7120871 0.78 FLT1 (0.69) FLT1IKBKBEGFR
SCHEMBL4075888 0.77 FLT1 (0.48) HTTNR2F2FLT1EGFR
SCHEMBL3930448 0.76 FLT1 (0.56) HTTLMNAALDH1A1SMN1; SMN2FLT1
SCHEMBL4072402 0.75 HTT (0.48) HTTLMNANR2F2FLT1IKBKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090042878-A1 THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR BAYER SHERING PHARMA AG (DE) 2009-02-12 US claimed
EP-2014663-A1 Thieno-pyrimidyl amines as modulators of EP2 receptors Bayer Schering Pharma AG (DE) 2009-01-14 EP claimed
US-20090042878-A1 THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR BAYER SHERING PHARMA AG (DE) 2009-02-12 US disclosed
US-20090042878-A1 THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR BAYER SHERING PHARMA AG (DE) 2009-02-12 US disclosed
US-20090042878-A1 THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR BAYER SHERING PHARMA AG (DE) 2009-02-12 US disclosed
EP-2014663-A1 Thieno-pyrimidyl amines as modulators of EP2 receptors Bayer Schering Pharma AG (DE) 2009-01-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042878-A1 THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR PTGER2, PTGER1, PTGDR2 CA1 4811/4885CA2 3345/4885CA7 4795/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.